309,064,000,000 DKK
valid: Two independent sources agree, or a primary source states it: the record asserts this claim.asserted
- Valid from
- 2025-12-31
- Valid until
- still holds
- Published
- 2026-02-04
- Recorded by AsOf
- 2026-11-08
- Checked
- 2026-11-08 · parsed from the SEC filing
- Confidence
- 0.95
Sources
Cite this claim
Plain text
AsOf. "Novo Nordisk revenue: 309,064,000,000 DKK", as of 2025-12-31. Claim clm_8F7EC31D7FFC, https://asof.is/claim/clm_8F7EC31D7FFC, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/0000353278-26-000012-index.htm.
APA
AsOf. (2025). Novo Nordisk revenue: 309,064,000,000 DKK (as of 2025-12-31) [Record clm_8F7EC31D7FFC]. Retrieved November 9, 2026, from https://asof.is/claim/clm_8F7EC31D7FFC (source: https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/0000353278-26-000012-index.htm)
BibTeX
@misc{asof_clm_8F7EC31D7FFC,
author = {AsOf},
title = {Novo Nordisk revenue: 309,064,000,000 DKK},
year = {2025},
howpublished = {\url{https://asof.is/claim/clm_8F7EC31D7FFC}},
note = {Claim clm\_8F7EC31D7FFC, as of 2025-12-31; source: https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/0000353278-26-000012-index.htm},
urldate = {2026-11-09}
}Supersedes
On the record
/claim/clm_8F7EC31D7FFC.md/v1/claims/clm_8F7EC31D7FFCsubmit a correction